BeOne Medicines Ltd. - Sponsored ADR ONC
360.85
0.88
0.24%
as of 25 Sep
- Market cap
- $37.3B
- P/E
- 61.2×
Follow ONC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
587.41 | 116.40 | 63.86 | 48.30 |
P/S ratio |
7.55 | 6.20 | 5.74 | 5.19 | |
P/FCF ratio |
71.58 | 35.95 | 30.10 | 24.27 | |
P/Operating CF |
93.28 | 79.39 | 163.66 | 68.70 | |
P/B ratio |
9.09 | 7.60 | 6.92 | 6.15 | |
Price to Tangible BV |
9.24 | 7.71 | 7.01 | 6.22 | |
EV/Sales |
6.91 | 5.66 | 5.19 | 4.61 | |
EV/EBITDA |
101.41 | 51.35 | 35.66 | 26.22 | |
EV/Operating CF |
43.73 | 26.82 | 23.20 | 19.05 | |
EV/FCF |
65.46 | 32.80 | 27.23 | 21.58 | |
Quick Ratio |
2.07 | 2.96 | 3.16 | 2.90 | |
Current Ratio |
2.39 | 3.41 | 3.64 | 3.41 | |
Net Debt/EBITDA |
(19.45) | (16.22) | (13.16) | (11.53) | |
Debt/Assets |
1.83% | 11.75% | 11.25% | 9.61% | |
Debt/Equity |
0.03 | 0.22 | 0.20 | 0.17 | |
Asset Turnover |
0.74 | 0.76 | 0.80 | 0.79 | |
Operating CF/Net income |
3.22 | 6.28 | 0.89 | 1.95 | |
Capex/Depreciation |
(1.29) | (1.04) | (0.99) | (0.68) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
37.08% | 41.08% | 35.76% | 35.91% | |
Selling, General and Administrative Expense of Revenue |
37.46% | 37.06% | 36.68% | 34.79% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.97% | 8.26% | 8.15% | 8.06% | |
Graham Net Nets |
0.06 | 0.07 | 0.09 | 0.10 | |
Graham Number |
22.11 | 48.46 | 67.00 | 78.46 | |
Earnings Yield |
0.17% | 0.86% | 1.57% | 2.07% | |
Free Cash Flow Yield |
1.40% | 2.78% | 3.32% | 4.12% | |
Revenue per Share |
12.81 | 13.74 | 13.64 | 15.28 | |
Operating CF per Share |
3.65 | 3.83 | 1.81 | 4.15 | |
Capex per Share |
(0.44) | (0.34) | (0.37) | (0.25) | |
Free Cash Flow per Share |
3.22 | 3.48 | 1.45 | 3.90 | |
Cash per Share |
36.63 | 41.70 | 43.18 | 45.69 | |
Shareholders Equity per Share |
37.47 | 39.99 | 42.90 | 46.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
37.47 | 39.99 | 42.90 | 46.37 | |
Free Cash Flow |
354.47 | 379.83 | 160.55 | 435.34 | |
Working Capital |
3,296.05 | 4,404.76 | 4,789.77 | 5,096.62 | |
Capital Expenditures |
(48.08) | (37.52) | (40.79) | (27.48) | |
Net Current Asset Value |
2,161.22 | 2,406.21 | 2,808.10 | 3,214.19 | |
EV/EBIT |
187.99 | 67.62 | 43.46 | 30.62 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 | |
Net Profit Margin |
8.84% | 4.44% | 15.02% | 13.90% | |
Price to Operating Income |
205.56 | 74.10 | 48.04 | 34.44 | |
| Other line items | |||||
Average Receivables |
716.16 | 770.68 | 827.63 | 913.48 | |
Average Payables |
345.60 | 442.02 | 394.02 | 415.54 | |
Average Inventory |
481.68 | 551.61 | 588.13 | 617.74 | |
Average Assets |
6,731.72 | 7,054.74 | 7,197.57 | 7,737.00 | |
Average Common Equity |
3,782.70 | 3,846.71 | 4,129.98 | 4,472.24 |
Columns are period end dates